Sodium–Glucose Cotransporter 2 Inhibitor Use Associated With Fournier's Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases
figure
posted on 2021-09-13, 18:10 authored by Bao Anh Tran, Wendy H. Updike, Krystal Bullers, Erini Serag-BolosSodium–glucose
cotransporter 2 (SGLT2) inhibitors are effective for glycemic control and have
demonstrated cardiorenal benefits. The U.S. Food and Drug Administration (FDA)
released a boxed warning in 2018 regarding the potential development
of Fournier’s gangrene (FG) with the use of SGLT2 inhibitors. FG is a serious perineal
infection with a mortality rate of up to 88% in some cases.
